Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor
Conference

CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE MKT:PLX) (TASE:PLX) today announced that Dr. David Aviezer, the
Company's President and Chief Executive Officer, will present at the 15^th
Annual BIO CEO and Investor Conference on Tuesday, February 12, 2013 at 11:30
AM ET. The conference is being held at the Waldorf Astoria Hotel in New York
City.A live webcast of the presentation will be available at www.protalix.com
on the event calendar page. A replay will be archived and available after the
conclusion of the presentation for 30 days.

About the BIO CEO & Investor Conference

The 15^th Annual BIO CEO & Investor Conference is the largest independent
investor conference focused on publicly-traded biotechnology companies.This
year's conference will feature corporate presentations from more than 140
leading biotechnology and pharmaceutical companies, Fireside Chats with
industry leaders, four Therapeutic Workshops and three Business Roundtables
all drawing from seasoned industry executives and analysts. New this year, a
special track of 25 high-caliber private companies will be presenting at the
event, and plenary sessions will address timely business issues and industry
trends. Attendees can expect many opportunities to schedule one-on-one
meetings as well as numerous networking opportunities. The conference is
designed to foster an informative dialogue between institutional investors and
senior biotechnology executives about emerging and current investment
opportunities.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx®. Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner. Protalix's first
approved product manufactured by ProCellEx, ELELYSO™ (taliglucerase alfa), an
enzyme replacement therapy for the treatment of Gaucher disease, was approved
for marketing by the U.S. Food and Drug Administration in May 2012, and by
Israel's Ministry of Health in September 2012. Additional marketing
applications for taliglucerase alfa have been filed in other
countries.Protalix is partnered with Pfizer Inc. for worldwide development
and commercialization, excluding Israel, where Protalix retains full
rights.Protalix's development pipeline also includes the following product
candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A
protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant
human acetylcholinesterase in development for several therapeutic and
prophylactic indications, a biodefense program and an organophosphate-based
pesticide treatment program; an orally-delivered glucocerebrosidase enzyme
that is naturally encased in carrot cells, also for the treatment of Gaucher
disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for
the treatment of certain immune diseases such as rheumatoid arthritis,
juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and
plaque psoriasis; and others.

CONTACT: Investor Contact
        
         Marcy Nanus
         The Trout Group, LLC
         646-378-2927
         mnanus@troutgroup.com
        
         Media Contact
        
         Kari Watson
         MacDougall Biomedical Communications
         781-235-3060
         kwatson@macbiocom.com